GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » Inventory-to-Revenue

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Inventory-to-Revenue : 2.56 (As of Mar. 2025)


View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Chongqing Genrix Biopharmaceutical Co's Average Total Inventories for the quarter that ended in Mar. 2025 was ¥51.56 Mil. Chongqing Genrix Biopharmaceutical Co's Revenue for the three months ended in Mar. 2025 was ¥20.16 Mil. Chongqing Genrix Biopharmaceutical Co's Inventory-to-Revenue for the quarter that ended in Mar. 2025 was 2.56.

Chongqing Genrix Biopharmaceutical Co's Inventory-to-Revenue for the quarter that ended in Mar. 2025 declined from Dec. 2024 (3.06) to Dec. 2024 (2.56)

A decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Chongqing Genrix Biopharmaceutical Co's Days Inventory for the three months ended in Mar. 2025 was 1,366.99.

Inventory Turnover measures how fast the company turns over its inventory within a year. Chongqing Genrix Biopharmaceutical Co's Inventory Turnover for the quarter that ended in Mar. 2025 was 0.07.


Chongqing Genrix Biopharmaceutical Co Inventory-to-Revenue Historical Data

The historical data trend for Chongqing Genrix Biopharmaceutical Co's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Genrix Biopharmaceutical Co Inventory-to-Revenue Chart

Chongqing Genrix Biopharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Inventory-to-Revenue
Get a 7-Day Free Trial 12.43 0.63 94.72 46.11 1.75

Chongqing Genrix Biopharmaceutical Co Quarterly Data
Dec19 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 9,611.50 9,967.00 4.70 3.06 2.56

Competitive Comparison of Chongqing Genrix Biopharmaceutical Co's Inventory-to-Revenue

For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chongqing Genrix Biopharmaceutical Co's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chongqing Genrix Biopharmaceutical Co's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Chongqing Genrix Biopharmaceutical Co's Inventory-to-Revenue falls into.


;
;

Chongqing Genrix Biopharmaceutical Co Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Chongqing Genrix Biopharmaceutical Co's Inventory-to-Revenue for the fiscal year that ended in Dec. 2024 is calculated as

Inventory-to-Revenue (A: Dec. 2024 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Dec. 2023 ) + Total Inventories (A: Dec. 2024 )) / count ) / Revenue (A: Dec. 2024 )
=( (55.451 + 50.149) / 2 ) / 30.095
=52.8 / 30.095
=1.75

Chongqing Genrix Biopharmaceutical Co's Inventory-to-Revenue for the quarter that ended in Mar. 2025 is calculated as

Inventory-to-Revenue (Q: Mar. 2025 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Dec. 2024 ) + Total Inventories (Q: Mar. 2025 )) / count ) / Revenue (Q: Mar. 2025 )
=( (50.149 + 52.978) / 2 ) / 20.156
=51.5635 / 20.156
=2.56

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chongqing Genrix Biopharmaceutical Co  (SHSE:688443) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Chongqing Genrix Biopharmaceutical Co's Days Inventory for the three months ended in Mar. 2025 is calculated as:

Days Inventory=Average Total Inventories (Q: Mar. 2025 )/Cost of Goods Sold (Q: Mar. 2025 )*Days in Period
=51.5635/3.442*365 / 4
=1,366.99

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Chongqing Genrix Biopharmaceutical Co's Inventory Turnover for the quarter that ended in Mar. 2025 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Mar. 2025 ) / Average Total Inventories (Q: Mar. 2025 )
=3.442 / 51.5635
=0.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chongqing Genrix Biopharmaceutical Co Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Chongqing Genrix Biopharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Executives
Jiang Ren Sheng Director

Chongqing Genrix Biopharmaceutical Co Headlines

No Headlines